By the end of March, the regulator could clear a highly anticipated pain drug from Vertex and a heart drug that’s critical to ...

Sangamo Therapeutics regains rights to its hemophilia A gene therapy as Pfizer ends their collaboration. The program showed ...

Back in October, Pfizer won the FDA’s favor on its own TFPI drug Hympavzi, which is specifically approved in hemophilia A or B patients who have not developed antibodies to previous inhibitor ...

Pfizer’s research ... Newer hemophilia drugs are entering the market, giving patients even more choices. Pfizer has one of them with Hympavzi, a once-weekly injectable drug approved by the FDA ...

Also Read: FDA Approves Pfizer’s Second Hemophilia Drug With Six Months In July 2024, Pfizer announced topline results from the Phase 3 AFFINE trial of giroctocogene fitelparvovec, which ...

Following Pfizer’s decision to end the collaboration ... Other Approved Gene Therapies to Treat Hemophilia Pfizer received FDA approval for two gene therapies for hemophilia, Hympavzi ...

The FDA has approved Johnson & Johnson’s prostate cancer drug Erleada (apalutamide ... who are also developing drugs for this niche - Pfizer/Astellas with Xtandi (enzalutamide), Bayer/Orion ...

Other Approved Gene Therapies to Treat Hemophilia Pfizer received FDA approval ... However, the drug has not been able to generate any significant sales for BioMarin in 2024. Sangamo’s another ...

Phase 3 study could pave the way for a Pfizer product to become the second US Food and Drug Administration (FDA)-approved gene therapy for hemophilia A. In an efficacy population of 50 patients ...